title: Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.
abstract: Non-typhoidal Salmonella (NTS) serovars S. Enteritidis and S. Typhimurium are a major cause of invasive bacterial disease (e.g., bacteremia, meningitis) in infants and young children in sub-Saharan Africa and also occasionally cause invasive disease in highly susceptible hosts (young infants, the elderly, and immunocompromised subjects) in industrialized countries. No licensed vaccines exist against human NTS infections. NTS core and O polysaccharide (COPS) and FliC (Phase 1 flagellin subunits) each constitute protective antigens in murine models. S. Enteritidis COPS conjugated to FliC represents a promising vaccine approach that elicits binding and opsonophagocytic antibodies and protects mice against lethal challenge with virulent S. Enteritidis. We examined the protective efficacy of fractional dosages of S. Enteritidis COPS:FliC conjugate vaccines in mice, and also established that protection can be passively transferred to naïve mice by administering sera from mice immunized with conjugate. Mice were immunized with three doses of either 10 µg, 2.5 µg (full dose), 0.25 µg, or 0.025 µg S. Enteritidis COPS:FliC conjugate at 28 day intervals. Antibody titers to COPS and FliC measured by ELISA fell consonant with progressively smaller vaccine dosage levels; anti-FliC IgG responses remained robust at fractional dosages for which anti-COPS serum IgG titers were decreased. Nevertheless, >90% protection against intraperitoneal challenge was observed in mice immunized with fractional dosages of conjugate that elicited diminished titers to both FliC and COPS. Passive transfer of immune sera from mice immunized with the highest dose of COPS:FliC to naïve mice was also protective, demonstrating the role of antibodies in mediating protection. These results provide important insights regarding the potency of Salmonella glycoconjugate vaccines that use flagellin as a carrier protein.
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America. rsimon@medicine.umaryland.edu
authors.forename: Raphael
authors.initials: R
authors.lastname: Simon
authors.forename: Jin Y
authors.initials: JY
authors.lastname: Wang
authors.forename: Mary A
authors.initials: MA
authors.lastname: Boyd
authors.forename: Mohan E
authors.initials: ME
authors.lastname: Tulapurkar
authors.forename: Girish
authors.initials: G
authors.lastname: Ramachandran
authors.forename: Sharon M
authors.initials: SM
authors.lastname: Tennant
authors.forename: Marcela
authors.initials: M
authors.lastname: Pasetti
authors.forename: James E
authors.initials: JE
authors.lastname: Galen
authors.forename: Myron M
authors.initials: MM
authors.lastname: Levine
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005408:Flagellin / Q000737:chemistry / Q000276:immunology*; D006001:Glycoconjugates / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D019081:O Antigens / Q000737:chemistry / Q000276:immunology*; D012481:Salmonella Infections, Animal / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022562:Salmonella Vaccines / Q000008:administration & dosage / Q000276:immunology*; D012477:Salmonella enteritidis / Q000187:drug effects / Q000276:immunology*; D014611:Vaccination; D018074:Vaccines, Conjugate
chemical_list: D000907:Antibodies, Bacterial; D006001:Glycoconjugates; D007106:Immune Sera; D007074:Immunoglobulin G; D019081:O Antigens; D022562:Salmonella Vaccines; D018074:Vaccines, Conjugate; D005408:Flagellin